{"url_path":"/sec/imux/8-k/2026-08-11/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-08-11","source_url":"https://www.sec.gov/Archives/edgar/data/1280776/0001193805-26-001071-index.html","accession_number":"0001193805-26-001071","cik":"0001280776","ticker":"IMUX","issuer_name":"IMMUNIC, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1280776/0001193805-26-001071-index.html","primary_entity_key":"0001280776","primary_entity_name":"IMMUNIC, INC."},"word_count":99,"has_tables":true,"body_markdown":"**Item 9.01. Financial Statements\nand Exhibits** \n\n \n\n**Exhibit**\n**Description**\n\n10.1            \n[Separation Agreement, dated as of August 7, 2026, between Immunic, Inc. and Dr. Daniel Vitt.](e665684_ex10-1.htm)              \n\n99.1            \n[Press Release dated August 10, 2026.](e665684_ex99-1.htm)\n\n99.3            \n[Press Release dated August 11, 2026](e665684_ex99-2.htm)\n\n104\nCover Page to this Current Report on Form 8-K in Inline XBRL.\n\n  \n\n \n\n  \n\n \n\n**SIGNATURES**\n\n \n\nPursuant to the requirements of the Securities Exchange Act of 1934,\nas amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.\n\n \n\nDated: August 11, 2026\n\n**Immunic, Inc.**\n\n \n \n \n\n \nBy:\n*/s/ Erik Lundgren*\n\n \n \nErik Lundgren\n\n \n \nChief Executive Officer"}